Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
dc.contributor.author | Rossing, Peter | |
dc.contributor.author | Agarwal, Rajiv | |
dc.contributor.author | Anker, Stefan D. | |
dc.contributor.author | Filippatos, Gerasimos | |
dc.contributor.author | Pitt, Bertram | |
dc.contributor.author | Ruilope, Luis M. | |
dc.contributor.author | Amod, Aslam | |
dc.contributor.author | Marre, Michel | |
dc.contributor.author | Joseph, Amer | |
dc.contributor.author | Lage, Andrea | |
dc.contributor.author | Scott, Charlie | |
dc.contributor.author | Bakris, George L. | |
dc.date.accessioned | 2022-01-06T15:51:42Z | |
dc.date.available | 2023-02-06 10:51:41 | en |
dc.date.available | 2022-01-06T15:51:42Z | |
dc.date.issued | 2022-01 | |
dc.identifier.citation | Rossing, Peter; Agarwal, Rajiv; Anker, Stefan D.; Filippatos, Gerasimos; Pitt, Bertram; Ruilope, Luis M.; Amod, Aslam; Marre, Michel; Joseph, Amer; Lage, Andrea; Scott, Charlie; Bakris, George L. (2022). "Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial." Diabetes, Obesity and Metabolism 24(1): 125-134. | |
dc.identifier.issn | 1462-8902 | |
dc.identifier.issn | 1463-1326 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/171231 | |
dc.description.abstract | AimsFinerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO‐DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use on the treatment effect of finerenone.Materials and MethodsPatients with type 2 diabetes, urine albumin‐to‐creatinine ratio (UACR) 30‐5000 mg/g and estimated glomerular filtration rate 25‐<75 ml/min per 1.73 m2 receiving optimized renin‐angiotensin system blockade were randomized to finerenone or placebo.ResultsOf the 5674 patients analysed, overall, 394 (6.9%) received GLP‐1RAs at baseline. A reduction in UACR with finerenone was observed with or without baseline GLP‐1RA use; ratio of least‐squares means 0.63 (95% confidence interval 0.56, 0.70) with GLP‐1RA use and 0.69 (95% confidence interval 0.67, 0.72) without GLP‐1RA use (p value for interaction .20). Finerenone also significantly reduced the primary kidney (time to kidney failure, sustained decrease in estimated glomerular filtration rate ≥40% from baseline, or renal death) and key secondary CV outcomes (time to CV death, non‐fatal myocardial infarction, non‐fatal stroke, or hospitalization for heart failure) versus placebo, with no clear difference because of GLP‐1RA use at baseline (p value for interaction .15 and .51 respectively) or any time during the trial. The safety profile of finerenone was similar between subgroups.ConclusionsThis exploratory subgroup analysis suggests that finerenone reduces UACR in patients with or without GLP‐1RA use at baseline, and the effects on kidney and CV outcomes are consistent irrespective of GLP‐1RA use. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.publisher | Blackwell Publishing Ltd | |
dc.subject.other | chronic kidney disease | |
dc.subject.other | type 2 diabetes | |
dc.subject.other | mineralocorticoid receptor antagonist | |
dc.subject.other | glucagon‐like peptide‐1 receptor agonist | |
dc.subject.other | finerenone | |
dc.title | Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Public Health (General) | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/171231/1/dom14558_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/171231/2/dom14558.pdf | |
dc.identifier.doi | 10.1111/dom.14558 | |
dc.identifier.source | Diabetes, Obesity and Metabolism | |
dc.identifier.citedreference | Guo C, Martinez‐Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006; 147 ( 11 ): 5363 ‐ 5373. | |
dc.identifier.citedreference | Kawanami D, Takashi Y. GLP‐1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms. Front Pharmacol. 2020; 11: 967. | |
dc.identifier.citedreference | Yin WL, Bain SC, Min T. The effect of glucagon‐like peptide‐1 receptor agonists on renal outcomes in type 2 diabetes. Diabetes Ther. 2020; 11 ( 4 ): 835 ‐ 844. | |
dc.identifier.citedreference | Schernthaner G, Shehadeh N, Ametov AS, et al. Worldwide inertia to the use of cardiorenal protective glucose‐lowering drugs (SGLT2i and GLP‐1 RA) in high‐risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020; 19 ( 1 ): 185. | |
dc.identifier.citedreference | Marso SP, Daniels GH, Brown‐Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375 ( 4 ): 311 ‐ 322. | |
dc.identifier.citedreference | Mann JFE, Orsted DD, Brown‐Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017; 377 ( 9 ): 839 ‐ S848. | |
dc.identifier.citedreference | Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo‐controlled trial. Lancet. 2019; 394 ( 10193 ): 131 ‐ 138. | |
dc.identifier.citedreference | Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‐blind, randomised placebo‐controlled trial. Lancet. 2019; 394 ( 10193 ): 121 ‐ 130. | |
dc.identifier.citedreference | Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375 ( 19 ): 1834 ‐ 1844. | |
dc.identifier.citedreference | Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7): a multicentre, open‐label, randomised trial. Lancet Diabetes Endocrinol. 2018; 6 ( 8 ): 605 ‐ 617. | |
dc.identifier.citedreference | Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2021; 17 ( 4 ): 227 ‐ 244. | |
dc.identifier.citedreference | Mann JFE, Hansen T, Idorn T, et al. Effects of once‐weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post‐hoc analysis of the SUSTAIN 1‐7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020; 8 ( 11 ): 880 ‐ 893. | |
dc.identifier.citedreference | Mann JFE, Muskiet MHA. Incretin‐based drugs and the kidney in type 2 diabetes: choosing between DPP‐4 inhibitors and GLP‐1 receptor agonists. Kidney Int. 2021; 99 ( 2 ): 314 ‐ 318. | |
dc.identifier.citedreference | Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021; 385: 896 ‐ 907. doi: 10.1056/NEJMoa2108269 | |
dc.identifier.citedreference | Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020; 98 ( 45 ): S1 ‐ S115. | |
dc.identifier.citedreference | Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020; 383: 2219 ‐ 2229. | |
dc.identifier.citedreference | Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021; 143 ( 6 ): 540 ‐ 552. | |
dc.identifier.citedreference | Barrera‐Chimal J, Estrela GR, Lechner SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin‐4 receptor signaling. Kidney Int. 2018; 93 ( 6 ): 1344 ‐ 1355. | |
dc.identifier.citedreference | Barrera‐Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019; 96 ( 2 ): 302 ‐ 319. | |
dc.identifier.citedreference | Buonafine M, Bonnard B, Jaisser F. Mineralocorticoid receptor and cardiovascular disease. Am J Hypertens. 2018; 31 ( 11 ): 1165 ‐ 1174. | |
dc.identifier.citedreference | Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non‐steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021; 42 ( 2 ): 152 ‐ 161. | |
dc.identifier.citedreference | Bakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the Finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019; 50 ( 5 ): 333 ‐ 344. | |
dc.identifier.citedreference | Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta‐analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019; 7 ( 2 ): 128 ‐ 139. | |
dc.identifier.citedreference | Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015; 314 ( 9 ): 884 ‐ 894. | |
dc.identifier.citedreference | Solomon SD, Lin J, Solomon CG, et al. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation. 2007; 116 ( 23 ): 2687 ‐ 2693. | |
dc.identifier.citedreference | Gansevoort RT, Correa‐Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382 ( 9889 ): 339 ‐ 352. | |
dc.identifier.citedreference | Parving HH, Lehnert H, Brochner‐Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345 ( 12 ): 870 ‐ 878. | |
dc.identifier.citedreference | Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358 ( 23 ): 2433 ‐ 2446. | |
dc.identifier.citedreference | de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014; 25 ( 5 ): 1083 ‐ 1093. | |
dc.identifier.citedreference | Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the Finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019; 50 ( 5 ): 345 ‐ 356. | |
dc.identifier.citedreference | Skov J, Pedersen M, Holst JJ, et al. Short‐term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab. 2016; 18 ( 6 ): 581 ‐ 589. | |
dc.identifier.citedreference | Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2020; 2: 487 ‐ 493. doi: 10.2337/dci19-0066 | |
dc.identifier.citedreference | KERENDIA. Prescribing Information. Whippany, NJ: Bayer Healthcare Pharmaceuticals Inc; 2021. | |
dc.identifier.citedreference | Gorriz JL, Soler MJ, Navarro‐Gonzalez JF, et al. GLP‐1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists. J Clin Med. 2020; 9 ( 4 ): 947. | |
dc.identifier.citedreference | Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, de Cosmo S. GLP‐1 receptor agonists and kidney protection. Medicina (Kaunas). 2019; 55 ( 6 ): 233. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.